Subsequent Events	12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 18. Subsequent Events On January 9, 2023, the Company entered into a Third Amendment to its Loan and Security Agreement with Hercules Capital Inc. The Third Amendment increased the size of the aggregate principal amount under the Loan Agreement from $300 million to $350 million reduced the interest rate, and extended the maturity and interest-only period of the Loan Agreement. $55.0 million was drawn upon the Third Amendment closing date. On February 21, 2023, the Company entered into a sublease agreement for office space for the Company's corporate and executive offices. On February 21, 2023, Axsome Malta Ltd., a Malta limited company (“Axsome Malta”), a wholly-owned subsidiary of the Company, entered into a License Agreement (the “License Agreement”) with Atnahs Pharma UK Limited (Pharmanovia), a company organized and existing under the laws of England and Wales (the “Licensee”), pursuant to which Axsome Malta will license certain Licensed Intellectual Property (as defined in the License Agreement) to the Licensee and grant an exclusive license to Licensee in the Territory (as defined in the License agreement to include Europe and certain countries in the Middle East and Africa) for use of the Licensed Intellectual property for the development and commercialization of the Company’s Licensed Products (as defined in the License Agreement and which includes the Company’s product Sunosi). The Company received an upfront payment of €62.0 million ($66.2 million) and is eligible to receive sales-based and other milestones totaling up to €94.5 million ($101.1 million). The Company will receive a royalty percentage in the mid-twenties on net sales of the Licensed Products (as defined in the License Agreement) in the Territory (as defined in the License Agreement).

Subsequent Events

12 Months Ended

Dec. 31, 2022

Note 18. Subsequent Events

On January 9, 2023, the Company entered into a Third Amendment to its Loan and Security Agreement with Hercules Capital Inc. The Third Amendment increased the size of the aggregate principal amount under the Loan Agreement from $300 million to $350 million reduced the interest rate, and extended the maturity and interest-only period of the Loan Agreement. $55.0 million was drawn upon the Third Amendment closing date.

On February 21, 2023, the Company entered into a sublease agreement for office space for the Company's corporate and executive offices.

On February 21, 2023, Axsome Malta Ltd., a Malta limited company (“Axsome Malta”), a wholly-owned subsidiary of the Company, entered into a License Agreement (the “License Agreement”) with Atnahs Pharma UK Limited (Pharmanovia), a company organized and existing under the laws of England and Wales (the “Licensee”), pursuant to which Axsome Malta will license certain Licensed Intellectual Property (as defined in the License Agreement) to the Licensee and grant an exclusive license to Licensee in the Territory (as defined in the License agreement to include Europe and certain countries in the Middle East and Africa) for use of the Licensed Intellectual property for the development and commercialization of the Company’s Licensed Products (as defined in the License Agreement and which includes the Company’s product Sunosi). The Company received an upfront payment of €62.0 million ($66.2 million) and is eligible to receive sales-based and other milestones totaling up to €94.5 million ($101.1 million). The Company will receive a royalty percentage in the mid-twenties on net sales of the Licensed Products (as defined in the License Agreement) in the Territory (as defined in the License Agreement).